New York, February 14, 2026, 14:27 EST — Market closed.
- AbbVie shares closed up 1.8% on Friday at $231.50, extending a two-session rebound.
- Executives used a Piper Sandler immunology conference to flag several trial readouts expected later this year.
- U.S. markets are shut Monday for Washington’s Birthday, with trading set to resume Tuesday.
AbbVie Inc. shares rose 1.8% on Friday to close at $231.50, a two-day climb that left the drugmaker’s stock near the top of its intraday range after touching $234.69. About 8.3 million shares changed hands.
The move matters now because AbbVie is heading into a holiday-shortened U.S. trading week with the stock back above $230 after a choppy stretch. Investors are hungry for near-term markers on the next round of clinical data, and they are looking for them in conference Q&As as much as in formal filings.
It also lands at a moment when big drugmakers have been treated as both “defensive” and “data-driven” — a mix that can flip fast when markets get jumpy. AbbVie’s pipeline cadence is part of the story traders will lean on when the tape starts moving again.
On Friday, AbbVie’s immunology leaders took questions at Piper Sandler’s Virtual Novel Targets in Immunology Symposium, with Roopal Thakkar and Kori Wallace representing the company and David Amsellem leading the discussion from Piper Sandler’s research team. “A good place to start… would be on data readouts as… the year progresses,” Amsellem said as he opened the session. (Seeking Alpha)
AbbVie pointed to Phase II testing — mid-stage studies designed to assess how well a drug works and help pick dosing — in hidradenitis suppurativa (HS), a chronic inflammatory skin disease, and laid out a stack of readouts it expects through the year. It also discussed work in inflammatory bowel disease (IBD) and described efforts around oral IL-23 inhibitors (targeting an immune signaling pathway) and CAR-T, an engineered immune-cell approach. The company also touched on the safety trade-offs that can come with stronger immune suppression as trials move into longer follow-up. (Investing)
The stock’s two-day bounce was noticeable in a week that saw sharp swings across sectors. AbbVie rose about 3% on Thursday and added another 1.8% on Friday, outpacing several large pharma peers in the last session while volume ran above its recent average, according to MarketWatch data. (MarketWatch)
Still, conference timelines are not outcomes. A weak efficacy signal, a safety surprise, or slower-than-expected adoption in key new uses can reset a stock quickly — especially when investors have been leaning on big pharma names as “steady” holdings.
Next week starts with a pause: the New York Stock Exchange is closed on Monday for Washington’s Birthday. That leaves fewer sessions for positioning before the next batch of healthcare headlines and sector flows hit screens. (New York Stock Exchange)
For AbbVie, the near-term test is straightforward: whether ABBV holds the $230 area when trading resumes on Tuesday, February 17, and whether buyers stick around once the conference circuit fades and the market goes looking for the next hard catalyst.
